Propanc Biopharma enters Series C Preferred Stock financing with Hexstone Capital

Propanc Biopharma, Inc.

Issues 100 shares of Series C Preferred convertible at lesser of $5.00 fixed or 85% of lowest trading price over conversion period.
Warrant issued to purchase up to 9,900 additional Series C shares at $10,000 per warrant share.
Company reserves shares equal to 200% of maximum conversion shares; closing subject to filing Certificate of Designation with Delaware.
Transaction includes Voting Agreement with officers/directors and Registration Rights Agreement for warrant shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.